Production & Sales

AstraZeneca, Takeda to develop MEDI1341 for Parkinson’s disease

AstraZeneca and Takeda Pharmaceutical have entered into an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

Celgene exercises option to extend strategic collaboration scope and term with Forma Therapeutics

Forma Therapeutics and Celgene announced an innovative R&D partnership in 2014 to pursue ground-breaking medicines in oncology and other therapeutic areas.

Gilead Sciences to buy Kite Pharma for $11.9bn

Biopharmaceutical firm Gilead Sciences has agreed to acquire US-based Kite Pharma for around $11.9bn.

Celgene, Sutro revise 2014 immuno-oncology collaboration

Celgene has revised the terms of its immuno-oncology collaboration with Sutro Biopharma, which was established in 2014.

Roche agrees to sell eczema drug rights to Dermira

Dermira has signed a licensing agreement with Roche to secure exclusive rights to lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications.

Emergent BioSolutions to buy GSK’s anthrax treatment raxibacumab

Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.

ABPI applies for Judicial Review against new procedures for cost-effective medicines

The Association of the British Pharmaceutical Industry (ABPI) has applied for judicial review over new procedures that restrict access to cost-effective medicines.

Pfizer breaks ground on new R&D facility in Missouri

Pfizer has broke ground on a research and development (R&D) and process development facility at 875 W. Chesterfield Parkway, Chesterfield in the US state of Missouri.

Eli Lilly completes $90m expansion of biotechnology center in San Diego

Eli Lilly and Company has completed the $90m expansion of its biotechnology center in San Diego, California, US.